Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
fda

Preservative-free formulation of ketamine, NRX-100, Granted FDA Fast-Track Designation for Suicidal Ideation in Patients with Depression, including Bipolar Depression

"Approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – designed to help address national crisis."
Michael DeMarco, PhD

by Michael DeMarco, PhD

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression
This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of…
Cision PR NewswireNRx Pharmaceuticals, Inc.

"NRx will be submitting patient-level data from controlled clinical trials that demonstrate ketamine to be superior to both a placebo and an active comparator, as well as either non-inferior or superior to electroshock therapy in treating various forms of depression, including patients with active suicidal ideation. Although ketamine in various forms is increasingly used to treat depression and related disorders, it is currently only approved by FDA only for use as an anesthetic and, therefore, not reimbursed by most insurance carriers for treatment of suicidality or depression. Intravenous ketamine is reimbursed by the Department of Veterans Affairs and the Department of Defense for its beneficiaries. By applying for FDA labeling for NRX-100 to treat suicidal depression, the Company hopes to make this potentially life-saving therapy available to all Americans, not just those who are able to pay out of pocket."

More like this

Spotlight: Nonresponse to Ketamine in Treatment-Resistant Bipolar Depression (Kachlick, et al, 2025)

Ketamine demonstrates a favorable safety and tolerability profile for short time use in TRBD regardless of isolated baseline characteristics, although a more severe comorbidity burden and benzodiazepine use appear to be associated with nonresponse.

Is ketamine a "psychedelic"?

Yes.
Spotlight: Long-term benefits of single-dose psilocybin in depressed patients with cancer (Agrawal, et al, 2025)

Spotlight: Long-term benefits of single-dose psilocybin in depressed patients with cancer (Agrawal, et al, 2025)

"These findings demonstrate robust antidepressive activity from a single 25 mg dose of psilocybin combined with psychotherapy and suggest a potentially paradigm-changing alternative to traditional antidepressants requiring further study."

Spotlight: UK Medical Cannabis Registry: A clinical outcomes analysis for insomnia (Aggarwal, et al, 2025)

"The study demonstrated improvements in subjective sleep quality and other captured PROMs in insomnia patients treated with cannabis-based medicinal products."

Spotlight: A Preliminary Approach to Oral Low-Dose Ketamine Self-Administration in Mice (Mus musculus) (Rocha, et al, 2025)

"No significant alterations were observed in liver and kidney function in either sex, nor in inflammation, apoptosis, or DNA damage in kidney tissues. Overall, these findings support the viability of voluntary oral ketamine administration and accentuate the need to refine the proposed model"

Spotlight: New and emerging pharmacologic treatments for MDD (Uyar, et al, 2025)

"Clinical trials have demonstrated the ability of ketamine to quickly reduce symptoms, particularly in treatment-resistant cases, with effects noticeable within hours and lasting several days post-administration."
Mastodon Mastodon